相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1
F. Andre et al.
ANNALS OF ONCOLOGY (2021)
Trial in progress: Phase I/II study of radiation therapy followed by intrathecal trastuzumab/pertuzumab in the management of HER2+breast leptomeningeal disease.
Kamran A. Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
PI3K inhibitors are finally coming of age
Bart Vanhaesebroeck et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database
M. Carausu et al.
ESMO OPEN (2021)
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
Preeti Narayan et al.
CLINICAL CANCER RESEARCH (2021)
Neutrophil recruitment and leukocyte response following focused ultrasound and microbubble mediated blood-brain barrier treatments
Charissa Poon et al.
THERANOSTICS (2021)
Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer
Emilie Le Rhun et al.
NEURO-ONCOLOGY (2020)
Atezolizumab for the treatment of breast cancer
Sangeetha M. Reddy et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
Ainhoa Madariaga et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Secondary effects on brain physiology caused by focused ultrasound-mediated disruption of the blood-brain barrier
Nick Todd et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K. Brastianos et al.
NATURE MEDICINE (2020)
Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression
Flora Zagouri et al.
CANCER TREATMENT REVIEWS (2020)
Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
Rachna Malani et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer
Sundee Dees et al.
MOLECULAR CANCER THERAPEUTICS (2020)
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts
Christoph Thomssen et al.
BREAST CARE (2020)
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang et al.
MOLECULAR CANCER (2019)
Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications
Adrienne Boire et al.
NEURO-ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
Yan Liu et al.
AGING-US (2019)
Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study
Todd Mainprize et al.
SCIENTIFIC REPORTS (2019)
Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis
Tomas Pascual et al.
JCO PRECISION ONCOLOGY (2019)
Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors
Christopher DeRenzo et al.
FRONTIERS IN IMMUNOLOGY (2019)
Intracranial evaluation of the in vivo pharmacokinetics, brain distribution, and efficacy of rucaparib in BRCA-mutant, triple-negative breast cancer
Minh Nguyen et al.
CANCER RESEARCH (2019)
Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models
Maria J. Sambade et al.
NEURO-ONCOLOGY ADVANCES (2019)
Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis
Pedro Exman et al.
NPJ BREAST CANCER (2019)
Blood-brain barrier disruption induced by diagnostic ultrasound combined with microbubbles in mice
Bingxia Zhao et al.
ONCOTARGET (2018)
Targeted shRNA-loaded liposome complex combined with focused ultrasound for blood brain barrier disruption and suppressing glioma growth
Guanjian Zhao et al.
CANCER LETTERS (2018)
Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germlineBRCAmutation
J Litton et al.
CANCER RESEARCH (2018)
Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?
Sheheryar Kabraji et al.
CLINICAL CANCER RESEARCH (2018)
Brainstem blood brain barrier disruption using focused ultrasound: A demonstration of feasibility and enhanced doxorubicin delivery
Saira Alli et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM)
Anna Niwinska et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Metastatic Brain Tumors Disrupt the Blood-Brain Barrier and Alter Lipid Metabolism by Inhibiting Expression of the Endothelial Cell Fatty Acid Transporter Mfsd2a
Shweta Tiwary et al.
SCIENTIFIC REPORTS (2018)
Buparlisib is a brain penetrable pan-PI3K inhibitor
Mark C. de Gooijer et al.
SCIENTIFIC REPORTS (2018)
Programming CAR-T cells to kill cancer
Louai Labanieh et al.
NATURE BIOMEDICAL ENGINEERING (2018)
Mechanisms of PARP inhibitor sensitivity and resistance
Alan D. D'Andrea
DNA REPAIR (2018)
Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.
Jeremy S. Abramson et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption
Costas D. Arvanitis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Low-Intensity MR-Guided Focused Ultrasound Mediated Disruption of the Blood-Brain Barrier for Intracranial Metastatic Diseases
Ying Meng et al.
FRONTIERS IN ONCOLOGY (2018)
PI3K: A master regulator of brain metastasis-promoting macrophages/microglia
Raquel Blazquez et al.
GLIA (2018)
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis
Francesca Poggio et al.
ESMO OPEN (2018)
Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 thorn Breast Cancer Metastasis to the Brain
Saul J. Priceman et al.
CLINICAL CANCER RESEARCH (2018)
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2-advanced breast cancer (BELLE-4)
M. Martin et al.
ANNALS OF ONCOLOGY (2017)
Disrupting the blood-brain barrier by focused ultrasound induces sterile inflammation
Zsofia I. Kovacs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
Mark E. Robson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe
Emilie Le Rhun et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Blood-BrainBarrier Closure TimeAfter Controlled Ultrasound-Induced Opening Is Independent of Opening Volume
Meaghan A. O'Reilly et al.
JOURNAL OF ULTRASOUND IN MEDICINE (2017)
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
Trisha M. Wise-Draper et al.
TARGETED ONCOLOGY (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Brain Metastases in Newly Diagnosed Breast Cancer A Population-Based Study
Allison M. Martin et al.
JAMA ONCOLOGY (2017)
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
E. Le Rhun et al.
ANNALS OF ONCOLOGY (2017)
DNA methyltransferases and their roles in tumorigenesis
Wu Zhang et al.
BIOMARKER RESEARCH (2017)
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
P. Vuylsteke et al.
ANNALS OF ONCOLOGY (2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
Avery D. Posey et al.
IMMUNITY (2016)
Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid
Elena I. Pentsova et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2016)
Integration of Breast Cancer Secretomes with Clinical Data Elucidates Potential Serum Markers for Disease Detection, Diagnosis, and Prognosis
Yvonne S. Ziegler et al.
PLOS ONE (2016)
Smart CARs engineered for cancer immunotherapy
Saul J. Priceman et al.
CURRENT OPINION IN ONCOLOGY (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target
Guo Chen et al.
CLINICAL CANCER RESEARCH (2014)
PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+breast cancer
Parvin F. Peddi et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Mfsd2a is critical for the formation and function of the blood-brain barrier
Ayal Ben-Zvi et al.
NATURE (2014)
The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer
Paul W. Sperduto et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Brain metastases free survival differs between breast cancer subtypes
A. Berghoff et al.
BRITISH JOURNAL OF CANCER (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Survival of breast cancer patients with meningeal carcinomatosis
H. Gauthier et al.
ANNALS OF ONCOLOGY (2010)
Heterogeneous Blood-Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer
Paul R. Lockman et al.
CLINICAL CANCER RESEARCH (2010)
HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors
Nabil Ahmed et al.
CLINICAL CANCER RESEARCH (2010)
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases
Brian Leyland-Jones
JOURNAL OF CLINICAL ONCOLOGY (2009)
Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer
S. Kyle et al.
BRITISH JOURNAL OF RADIOLOGY (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Chemotherapy delivery issues in central nervous system malignancy: A reality check
Leslie L. Muldoon et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier
Hans-Joachim Stemmler et al.
ANTI-CANCER DRUGS (2007)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications
K Hynynen et al.
NEUROIMAGE (2005)
Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles
N Sheikov et al.
ULTRASOUND IN MEDICINE AND BIOLOGY (2004)
Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits
K Hynynen et al.
RADIOLOGY (2001)
分享论文
